Breaking News, Promotions & Moves

CureVac Appoints CDO

Voliotis to lead global product development efforts to advance pipeline of mRNA-based products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dimitris Voliotis, M.D., has been appointed chief development officer, CureVac AG. Dr. Voliotis will lead the company’s R&D activities from discovery to regulatory filing and serve on the executive team. Dr. Voliotis will be based at the company’s Boston location, travelling regularly to the Germany-based sites in Tübingen and Frankfurt. “We are excited to welcome Dimitris to CureVac. He is a highly experienced leader with a strong track record in drug development and regulatory approvals...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters